Maris William J's Form 4 filing
DA32 Life Science Tech Acquisition Corp. (DALS) · filed Aug 3, 2021
- Accession no.
- 0000899243-21-031450
- Filed
- Aug 3, 2021, 9:47 PM ET
- Trade date
- Jul 30, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $8.00M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maris William JCIK 0001722210 | Director, 10% Owner, Other: Director by Deputization |
| Section 32 Fund 3, LPCIK 0001808115 | Director, 10% Owner, Other: Director by Deputization |
| Section 32 GP 3, LLCCIK 0001808116 | Director, 10% Owner, Other: Director by Deputization |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 30, 2021 | Class A Common Stock | PPurchaseAcquired | +800,000 | $10.00 | +$8,000,000 | 800,000 | Direct | |
| Jul 30, 2021 | Class A Common Stock | AGrant or awardAcquired | +650,000 | $10.00 | +$6,500,000 | 1,450,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
See Exhibit 99.1 - Joint Filer Information, which is incorporated herein by reference and describes in further detail the relationships of the Reporting Persons to the Issuer. Henrikki Harsu, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24.1, 24.2 and 24.3 to a Form 3 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on July 27, 2021 by Section 32 Fund 3, LP, Section 32 GP 3, LLC and William J Maris. Steve Kafka, an employee of Section 32 Fund 3, LP, serves as a director of the Issuer.